ASX Share rice
Sun 01 Aug 2021 - 06:42:pm (Sydney)

ZLD Share Price

ZELIRA THERAPEUTICS LIMITEDZLDPharmaceuticals, Biotechnology & Life Sciences

ZLD Company Information

Name:

Zelira Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

101 St Georges Terrace Perth WA Australia 6000

Phone:

61 8 6558 0886

Founder & Chairman:

Mr. Osagie O. Imasogie

Co-Founder & Non-Exec. Deputy Chairman:

Mr. Harry Karelis B.Sc (Hons), MBA, CFA, F.Fin, FAICD

Co-Founder & Non-Exec. Director:

Mr. Jason William Peterson

CEO of USA, MD of USA & Director:

Dr. Oludare Odumosu

Company Sec.:

Mr. Timothy Ryan Slate

Clinical Trial Consultant:

Dr. Patty Washer

Company Overview:

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.

ZLD Share Price Information

Shares Issued:

1.19B

Market Capitalisation:

$52.37M

Revenue (TTM):

$1.07M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.005

Operating Margin (TTM):

$-7.87

Return On Assets (TTM):

$-0.14

Return On Equity (TTM):

$-0.21

Quarterly Revenue Growth (YOY):

-0.934

Gross Profit(TTM):

$0.98M

Diluted Earnings Per Share (TTM):

$-0.008

ZLD CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$1.11M

Change To Liabilities:

$-50,111

Total Cashflow From Investing Activities:

$1.11M

Net Income:

$-7,015,045

Total Cash From Operating Activities:

$-6,936,276

Depreciation:

$275.05K

Other Cashflow From Investing Activities:

$0.93M

Change To Account Receivables:

$-84,254

Sale Purchase Of Stock:

$-286,702

Capital Expenditures:

$15.97K

ZLD Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-7,015,045

Net Income:

$-7,015,045

Operating Income:

$-7,936,793

Other Operating Expenses:

$98.28K

Interest Expense:

$12.34K

Total Revenue:

$1.04M

Total Operating Expenses:

$7.94M

ZLD Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$1.28M

Total Liabilities:

$1.24M

Total Stockholder Equity:

$34.55M

Other Current Liabilities:

$50K

Total Assets:

$35.79M

Common Stock:

$26.08M

Other Current Assets:

$1.10K

Retained Earnings:

$-18,699,876

Good Will:

$30.75M

Cash:

$1.70M

Total Current Liabilities:

$670.25K

Property - Plant & Equipment:

$1.58M

Net Tangible Assets:

$2.52M

Long-Term Investments:

$350.35K

Total Current Assets:

$1.83M

Net Receivables:

$64.14K

Short-Term Investments:

$33.96M

Accounts Payable:

$559.39K

Short-Term Investments:

$33.96

Non Current Liabilities Total:

$571.46K

ZLD Share Price History

ZLD News

29 Jun, 2021
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
31 Dec, 2020
Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...
15 Dec, 2020
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.